HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals has reported significant advancements in their clinical trials, including the addition of a prestigious US medical center to accelerate their HEMO-CAR-T studies, potential expansion into pediatric leukemia treatments, and progress in their CBR platform and CDX bispecific antibody program aimed at combating rare cancers and viral infections. The company’s dedication to developing innovative treatments for severe diseases is underscored by their CEO’s remarks on their commitment to non-dilutive financing to support ongoing initiatives and bring their scientific discoveries to clinical success.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
